Modality
Cell Therapy
MOA
PI3Ki
Target
TIM-3
Pathway
Autophagy
Melanoma
Development Pipeline
Preclinical
~Dec 2020
→ ~Mar 2022
Phase 1
~Jun 2022
→ ~Sep 2023
Phase 2
Dec 2023
→ Jul 2031
Phase 2Current
NCT05252502
1,209 pts·Melanoma
2023-12→2031-07·Recruiting
1,209 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2031-07-055.3y awayPh3 Readout· Melanoma
Trial Timeline
2024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3
P2/3
Recruit…
Catalysts
Ph3 Readout
2031-07-05 · 5.3y away
Melanoma
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05252502 | Phase 2/3 | Melanoma | Recruiting | 1209 | SeizFreq |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| REG-3155 | Regeneron | Phase 1/2 | MDM2 | |
| REG-6699 | Regeneron | Phase 2/3 | TIM-3 | |
| SRP-3270 | Sarepta | Phase 1/2 | SGLT2 | |
| Nidasacituzumab | United Therapeutics | Phase 1/2 | TIM-3 | |
| Semainavolisib | Krystal Biotech | Phase 2 | B7-H3 |